Complexity of cancer stem cells

International Journal of Cancer

Volumn 132, Issue 6, 2013, Pages 1249-1259

  Sugihara, Eiji ^a,b   Saya, Hideyuki ^a,b  

^a KEIO UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

cancer stem cell; cell of origin; clonal diversity; CSC targeted therapy; plasticity

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A5; ALDEHYDE DEHYDROGENASE; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CELL SURFACE PROTEIN; CYTARABINE; HERMES ANTIGEN; NUCLEAR PROTEIN; PROTEIN JARID1B; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW; BRAIN TUMOR; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CELL ACTIVITY; CELL CLONE; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL HETEROGENEITY; CELL ISOLATION; CELL LINEAGE; CELL PROLIFERATION; CELL RENEWAL; CELL SELECTION; CELL SUBPOPULATION; CELLULAR DISTRIBUTION; CHORIOCARCINOMA; COLONY FORMATION; CYTOLOGY; ENZYME ACTIVITY; EPITHELIUM CELL; EXPERIMENTAL MOUSE; GENETIC VARIABILITY; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; LYMPHOMA; MOLECULARLY TARGETED THERAPY; MYELOMA; NEURAL STEM CELL; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL RESEARCH; STROMA CELL; TROPHOBLAST; TUMOR CELL; TUMOR CLASSIFICATION; TUMOR XENOGRAFT;

ANIMALS; CELL SEPARATION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; NEOPLASMS; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; REPRESSOR PROTEINS;

EID: 84872919631     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27961     Document Type: Article

References (83)

1. Nowell PC,. The clonal evolution of tumor cell populations. Science 1976; 194: 23-8.
2. Dick JE,. Stem cell concepts renew cancer research. Blood 2008; 112: 4793-807.
3. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-44. (Pubitemid 44623625)
4. Bruce WR, Van Der Gaag H,. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 1963; 199: 79-80.
5. Park CH, Bergsagel DE, McCulloch EA,. Mouse myeloma tumor stem cells: A primary cell culture assay. J Natl Cancer Inst 1971; 46: 411-22.
6. Sabbath KD, Ball ED, Larcom P, et al. Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J Clin Invest 1985; 75: 746-53. (Pubitemid 15142089)
7. Griffin JD, Lowenberg B,. Clonogenic cells in acute myeloblastic leukemia. Blood 1986; 68: 1185-95. (Pubitemid 17228790)
8. Bonnet D, Dick JE,. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7. (Pubitemid 27298715)
9. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-8. (Pubitemid 36418143)
10. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-8. (Pubitemid 37187480)
11. Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006; 25: 1696-708.
12. Hurt EM, Kawasaki BT, Klarmann GJ, et al. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008; 98: 756-65. (Pubitemid 351272625)
13. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-15. (Pubitemid 46067311)
14. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
15. Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005; 65: 4320-33. (Pubitemid 40775671)
16. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature 2008; 451: 345-9.
17. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51. (Pubitemid 41713363)
18. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, et al. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007; 67: 6796-805. (Pubitemid 47105527)
19. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-15. (Pubitemid 46815044)
20. Joo KM, Kim SY, Jin X, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 2008; 88: 808-15.
21. Eppert K, Takenaka K, Lechman ER, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011; 17: 1086-93.
22. Huntly BJ, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004; 6: 587-96. (Pubitemid 40017702)
23. Somervaille TC, Cleary ML,. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006; 10: 257-68. (Pubitemid 44512188)
24. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006; 9: 391-403. (Pubitemid 43668737)
25. Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-34. (Pubitemid 32937383)
26. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101: 14228-33. (Pubitemid 39305058)
27. Kondo T, Setoguchi T, Taga T,. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004; 101: 781-6. (Pubitemid 38121035)
28. Pearce DJ, Taussig D, Simpson C, et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005; 23: 752-60. (Pubitemid 40791790)
29. Cheung AM, Wan TS, Leung JC, et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007; 21: 1423-30. (Pubitemid 46965282)
30. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-67. (Pubitemid 350056407)
31. Ma I, Allan AL,. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 2011; 7: 292-306.
32. Tanei T, Morimoto K, Shimazu K, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 2009; 15: 4234-41.
33. Croker AK, Goodale D, Chu J, et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 2009; 13: 2236-52.
34. Silva IA, Bai S, McLean K, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011; 71: 3991-4001.
35. Welte Y, Adjaye J, Lehrach HR, et al. Cancer stem cells in solid tumors: elusive or illusive? Cell Commun Signal 2010; 8: 6.
36. Brescia P, Richichi C, Pelicci G,. Current strategies for identification of glioma stem cells: Adequate or unsatisfactory? J Oncol 2012; 2012: 376894.
37. Schepers AG, Snippert HJ, Stange DE, et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. Science 2012; 337: 730-5.
38. Huntly BJ, Gilliland DG,. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005; 5: 311-21. (Pubitemid 40488636)
39. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442: 818-22. (Pubitemid 44258912)
40. Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia. Blood 2000; 95: 1007-13. (Pubitemid 30062725)
41. Cox CV, Evely RS, Oakhill A, et al. Characterization of acute lymphoblastic leukemia progenitor cells. Blood 2004; 104: 2919-25. (Pubitemid 39434980)
42. Castor A, Nilsson L, Astrand-Grundstrom I, et al. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 2005; 11: 630-7. (Pubitemid 40868303)
43. Hong D, Gupta R, Ancliff P, et al. Initiating and cancer-propagating cells in TEL-AML1-Associated childhood leukemia. Science 2008; 319: 336-9.
44. le Viseur C, Hotfilder M, Bomken S, et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell 2008; 14: 47-58. (Pubitemid 351885495)
45. Sugihara E, Shimizu T, Kojima K, et al. Ink4a and Arf are crucial factors in the determination of the cell of origin and the therapeutic sensitivity of Myc-induced mouse lymphoid tumor. Oncogene 2012; 31: 2849-61.
46. Visvader JE,. Cells of origin in cancer. Nature 2011; 469: 314-22.
47. Mullighan CG, Williams RT, Downing JR, et al. Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev 2008; 22: 1411-15. (Pubitemid 351793074)
48. Fang D,. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005; 65: 9328-37. (Pubitemid 41508000)
49. Monzani E, Facchetti F, Galmozzi E, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007; 43: 935-46. (Pubitemid 46366698)
50. Boiko AD, Razorenova OV, van de Rijn M, et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010; 466: 133-7.
51. Shultz LD, Lyons BL, Burzenski LM, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005; 174: 6477-89. (Pubitemid 40663843)
52. Quintana E, Shackleton M, Sabel MS, et al. Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-8.
53. Quintana E, Shackleton M, Foster HR, et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010; 18: 510-23.
54. Roesch A, Becker B, Meyer S, et al. Retinoblastoma-binding protein 2-homolog 1: A retinoblastoma-binding protein downregulated in malignant melanomas. Mod Pathol 2005; 18: 1249-57. (Pubitemid 43079925)
55. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010; 141: 583-94.
56. Cabarcas SM, Mathews LA, Farrar WL,. The cancer stem cell niche-there goes the neighborhood? Int J Cancer 2011; 129: 2315-27.
57. Mani SA, Guo W, Liao M-J, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15. (Pubitemid 351636299)
58. Xia X, Lemieux ME, Li W, et al. Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci USA 2009; 106: 4260-5.
59. Takahashi K, Yamanaka S,. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-76. (Pubitemid 44233629)
60. Wong DJ, Segal E, Chang HY,. Stemness, cancer and cancer stem cells. Cell Cycle 2008; 7: 3622-4.
61. Shimizu T, Ishikawa T, Sugihara E, et al. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene 2010; 29: 5687-99.
62. Sampetrean O, Saga I, Nakanishi M, et al. Invasion precedes tumor mass formation in a malignant brain tumor model of genetically modified neural stem cells. Neoplasia 2011; 13: 784-91.
63. Motohara T, Masuko S, Ishimoto T, et al. Transient depletion of p53 followed by transduction of c-Myc and K-Ras converts ovarian stem-like cells into tumor-initiating cells. Carcinogenesis 2011; 32: 1597-606.
64. Kobayashi Y, Shimizu T, Naoe H, et al. Establishment of a choriocarcinoma model from immortalized normal extravillous trophoblast cells transduced with HRASV12. Am J Pathol 2011; 179: 1471-82.
65. Aikawa Y, Katsumoto T, Zhang P, et al. PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2. Nat Med 2010; 16: 580-5, 1p following 5.
66. Kikushige Y, Shima T, Takayanagi S, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell 2010; 7: 708-17.
67. Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009; 138: 271-85.
68. Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009; 138: 286-99.
69. Ishimoto T, Nagano O, Yae T, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011; 19: 387-400.
70. Saito Y, Uchida N, Tanaka S, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 2010; 28: 275-80.
71. Ito K, Bernardi R, Morotti A, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008; 453: 1072-8. (Pubitemid 351871736)
72. Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676-80.
73. Gilbertson RJ, Rich JN,. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007; 7: 733-6. (Pubitemid 47463683)
74. Bao S,. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66: 7843-8. (Pubitemid 44299144)
75. Burger JA, Peled A,. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009; 23: 43-52.
76. Hwang-Verslues WW, Kuo WH, Chang PH, et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One 2009; 4: e8377.
77. Lotem J, Sachs L,. Epigenetics and the plasticity of differentiation in normal and cancer stem cells. Oncogene 2006; 25: 7663-72. (Pubitemid 44967961)
78. Baylin SB, Jones PA,. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11: 726-34.
79. Rodriguez-Paredes M, Esteller M,. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17: 330-9.
80. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011; 469: 356-61.
81. Notta F, Mullighan CG, Wang JCY, et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 2011; 469: 362-7.
82. Dieter SM, Ball CR, Hoffmann CM, et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011; 9: 357-65.
83. Magee JA, Piskounova E, Morrison SJ,. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21: 283-96.